Most pharmas shrug off headwinds

Posted 18 June 2025 PM

Trump's war on the pharmaceutical industry has filled headlines recently, but is yet to make an impact on the industry's financial statements. Most pharmas posted solid year-on-year growth in the first quarter of 2025, with one seeing revenues head for the stratosphere.

Eli Lilly saw its first quarter revenues surge 45 per cent year-on-year, bringing in $19.77 billion (US$12.73 billion). In no surprise, the growth was driven by booming sales of Mounjaro and Zepbound, as Lilly takes the pole position in the obesity market and a study demonstrated higher weight loss compared to Wegovy.

To see the whole article, please login